Boston Partners Sells 1,556,246 Shares of CareDx, Inc. $CDNA

CareDx logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Boston Partners cut its CareDx stake by 80.3%, selling 1,556,246 shares in the third quarter and retaining 381,355 shares valued at about $24.8 million.
  • CareDx reported quarterly EPS of $0.70, beating the $0.25 consensus, while revenue rose 39.3% year over year to $139.36 million.
  • CareDx insiders sold 83,143 shares worth about $6.48 million over the quarter. Analysts’ consensus rating was “Moderate Buy,” with a $70.33 average price target.
  • MarketBeat previews top five stocks to own in December.

Boston Partners trimmed its holdings in shares of CareDx, Inc. (NASDAQ:CDNA - Free Report) by 80.3% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 381,355 shares of the company's stock after selling 1,556,246 shares during the period. Boston Partners owned 0.73% of CareDx worth $24,786,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Nykredit A S acquired a new stake in shares of CareDx in the second quarter valued at $25,000. Integrated Wealth Concepts LLC acquired a new position in CareDx during the 2nd quarter worth about $29,000. Reyes Financial Architecture Inc. bought a new stake in CareDx during the 3rd quarter worth about $50,000. Signaturefd LLC bought a new stake in CareDx during the 3rd quarter worth about $51,000. Finally, Global Retirement Partners LLC increased its position in CareDx by 11,955.6% in the 3rd quarter. Global Retirement Partners LLC now owns 1,085 shares of the company's stock valued at $71,000 after acquiring an additional 1,076 shares in the last quarter.

Insider Activity at CareDx

In related news, CFO Keith Kennedy sold 2,097 shares of the stock in a transaction that occurred on Thursday, November 12th. The shares were sold at an average price of $79.29, for a total value of $166,271.13. Following the sale, the chief financial officer directly owned 199,147 shares in the company, valued at $15,790,365.63. This trade represents a 1.04% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Michael Goldberg sold 13,800 shares of CareDx stock in a transaction that occurred on Thursday, November 12th. The stock was sold at an average price of $79.15, for a total transaction of $1,092,270.00. Following the transaction, the director directly owned 48,526 shares in the company, valued at $3,840,832.90. The trade was a 22.14% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 83,143 shares of company stock worth $6,475,506. 2.40% of the stock is owned by insiders.

CareDx Price Performance

Shares of NASDAQ CDNA opened at $69.85 on Friday. The company's 50 day simple moving average is $68.60 and its 200 day simple moving average is $38.01. CareDx, Inc. has a fifty-two week low of $15.56 and a fifty-two week high of $90.87. The firm has a market capitalization of $3.67 billion, a P/E ratio of 29.22 and a beta of 2.51.

CareDx (NASDAQ:CDNA - Get Free Report) last issued its earnings results on Thursday, October 29th. The company reported $0.70 EPS for the quarter, beating the consensus estimate of $0.25 by $0.45. The company had revenue of $139.36 million during the quarter, compared to analysts' expectations of $121.96 million. CareDx had a net margin of 25.86% and a return on equity of 9.74%. The business's revenue for the quarter was up 39.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.03 EPS. Sell-side analysts expect that CareDx, Inc. will post 1.00 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on CDNA. Craig Hallum upgraded shares of CareDx from a "hold" rating to a "buy" rating and set a $64.00 target price on the stock in a research report on Monday, August 3rd. Zacks Research upgraded shares of CareDx from a "hold" rating to a "strong-buy" rating in a research report on Thursday, November 5th. HC Wainwright reiterated a "neutral" rating and issued a $46.00 price objective on shares of CareDx in a research report on Friday, July 31st. Wall Street Zen cut CareDx from a "strong-buy" rating to a "buy" rating in a research note on Saturday, October 31st. Finally, BTIG Research boosted their target price on CareDx from $81.00 to $92.00 and gave the stock a "buy" rating in a research report on Friday, October 30th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $70.33.

Check Out Our Latest Analysis on CareDx

About CareDx

(Free Report)

CareDx, Inc. is a precision medicine company focused on organ transplantation. It develops and provides diagnostic tests and related services to help clinicians assess transplant recipients and monitor their health over time. Its offerings include AlloSure, a donor-derived cell-free DNA test used to help monitor for organ rejection, and AlloMap, a gene-expression test used in heart transplant care. CareDx also provides histocompatibility testing, clinical tools, and services designed to support patients and transplant care teams.

Featured Stories

Want to see what other hedge funds are holding CDNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CareDx, Inc. (NASDAQ:CDNA - Free Report).

Institutional Ownership by Quarter for CareDx (NASDAQ:CDNA)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in CareDx Right Now?

Before you consider CareDx, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CareDx wasn't on the list.

While CareDx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines